WO2023041657 - ALKYLATED HALOQUINOLINES FOR USE IN EPILEPSY
National phase entry is expected:
Publication Number
WO/2023/041657
Publication Date
23.03.2023
International Application No.
PCT/EP2022/075665
International Filing Date
15.09.2022
Title **
[English]
ALKYLATED HALOQUINOLINES FOR USE IN EPILEPSY
[French]
HALOQUINOLINES ALKYLÉS DESTINÉS À ÊTRE UTILISÉS CONTRE L'ÉPILEPSIE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
KU Leuven Research & Development Waaistraat 6 - Box 5105
3000 Leuven, BE
Inventors
THEVISSEN, Karin
Ezelbergstraat 14
3360 Bierbeek, BE
CAMMUE, Bruno
J.B. Woutersstraat 109A
1652 Alsemberg, BE
NY, Annelii
Karlsruhelaan 21
2400 Mol, BE
LAGAE, Lieven
Boslaan 15A
3050 Oud-Heverlee, BE
DE WITTE, Peter
Predikherenberg 25
3010 Kessel-Lo, BE
Priority Data
21196909.2
15.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1174 | |
| EPO | Filing, Examination | 5066 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 10119 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to alkylated haloquinolines for use in the prevention or treatment of a seizure in epilepsy or in neuroinflammation associated with epilepsy.[French]
L'invention concerne des haloquinolines alkylés destinés à être utilisées dans la prévention ou le traitement d'une crise d'épilepsie ou d'une neuro-inflammation associée à l'épilepsie.